Stephen Lev Hoffman
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$29.9MFederal grants as PI38 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
38 awards · $29.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 12, 2024 | NIH | SBIR Phase I Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro | $278K | SANARIA INC. |
| Jul 12, 2024 | NIH | SBIR Phase II A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | $968K | SANARIA INC. |
| Sep 6, 2023 | NIH | SBIR Phase I Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro | $282K | SANARIA INC. |
| Jun 14, 2023 | NIH | SBIR Phase II A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | $968K | SANARIA INC. |
| Apr 27, 2023 | NIH | SBIR Phase II Automating mosquito microdissection for a malaria PfSPZ vaccine | $958K | SANARIA INC. |
| Jul 5, 2022 | NIH | SBIR Phase II A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | $999K | SANARIA INC. |
| May 18, 2022 | NIH | SBIR Phase II In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | $947K | SANARIA INC. |
| Apr 25, 2022 | NIH | SBIR Phase II Automating mosquito microdissection for a malaria PfSPZ vaccine | $966K | SANARIA INC. |
| Aug 16, 2021 | NIH | SBIR Phase I Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture | $300K | SANARIA INC. |
| May 21, 2021 | NIH | SBIR Phase II Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | $977K | SANARIA INC. |
| May 21, 2021 | NIH | SBIR Phase II In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | $966K | SANARIA INC. |
| Apr 30, 2021 | NIH | SBIR Phase II Automating mosquito microdissection for a malaria PfSPZ vaccine | $1.0M | SANARIA INC. |
| Apr 6, 2021 | NIH | SBIR Phase I A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage. | $300K | SANARIA INC. |
| Aug 14, 2020 | NIH | SBIR Phase I Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture | $300K | SANARIA INC. |
| Jun 15, 2020 | NIH | SBIR Phase II In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | $1.0M | SANARIA INC. |
| May 29, 2020 | NIH | SBIR Phase II Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | $999K | SANARIA INC. |
| Apr 21, 2020 | NIH | SBIR Phase I A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage. | $300K | SANARIA INC. |
| Apr 24, 2019 | NIH | SBIR Phase II Automating mosquito microdissection for a malaria PfSPZ vaccine | $976K | SANARIA INC. |
| Jan 31, 2019 | NIH | SBIR Phase I Development, GMP manufacture, and quality control release of a triple knock out genetically attenuated Plasmodium falciparum sporozoite vaccine | $300K | SANARIA INC. |
| May 31, 2018 | NIH | SBIR Phase II A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine | $1.0M | SANARIA INC. |
| May 31, 2018 | NIH | SBIR Phase II Universal Attenuated Sporozoite Vaccine and Challenge System | $951K | SANARIA INC. |
| May 31, 2018 | NIH | SBIR Phase II Automating mosquito microdissection for a malaria PfSPZ vaccine | $988K | SANARIA INC. |
| Mar 7, 2018 | NIH | SBIR Phase I Development, GMP manufacture, and quality control release of a triple knock out genetically attenuated Plasmodium falciparum sporozoite vaccine | $300K | SANARIA INC. |
| Jun 20, 2017 | NIH | SBIR Phase II Automating mosquito microdissection for a malaria PfSPZ vaccine | $998K | SANARIA INC. |
| Jun 1, 2017 | NIH | SBIR Phase II A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine | $1.0M | SANARIA INC. |
| May 15, 2017 | NIH | SBIR Phase II Universal Attenuated Sporozoite Vaccine and Challenge System | $970K | SANARIA INC. |
| Apr 26, 2017 | NIH | SBIR Phase I Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI) | $300K | SANARIA INC. |
| Dec 27, 2016 | NIH | SBIR Phase II Genetically Attenuated PfSPZ Malaria Vaccine | $1000K | SANARIA INC. |
| Dec 23, 2016 | NIH | SBIR Phase II In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | $1000K | SANARIA INC. |
| Jun 16, 2016 | NIH | SBIR Phase II A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine | $1.0M | SANARIA INC. |
| Jun 14, 2016 | NIH | SBIR Phase II Universal Attenuated Sporozoite Vaccine and Challenge System | $989K | SANARIA INC. |
| Apr 22, 2016 | NIH | SBIR Phase I Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI) | $300K | SANARIA INC. |
| Dec 21, 2015 | NIH | SBIR Phase II In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | $1000K | SANARIA INC. |
| Dec 21, 2015 | NIH | SBIR Phase II Genetically Attenuated PfSPZ Malaria Vaccine | $1000K | SANARIA INC. |
| Jul 16, 2015 | NIH | SBIR Phase II Plasmodium Falciparum Whole Sporozoite Malaria Vaccine | $1000K | SANARIA INC. |
| Jan 21, 2015 | NIH | SBIR Phase I Automating mosquito microdissection for a malaria PfSPZ vaccine | $300K | SANARIA INC. |
| Jan 13, 2015 | NIH | SBIR Phase II Genetically Attenuated PfSPZ Malaria Vaccine | $1000K | SANARIA INC. |
| Jan 13, 2015 | NIH | SBIR Phase II In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | $1000K | SANARIA INC. |
Peer ranks
Federal funding#1
Awards as PI#2
Patents#273
Companies
- SANARIA INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.